PIA
ACRS icon

Piedmont Investment Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Piedmont Investment Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-464
Closed -$9K – 1058
2018
Q2 		$9K Buy
+464
New +$8.57K ﹤0.01% 1853

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Piedmont Investment Advisors's ACRS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 464 shares — an estimated $9K sold.

Piedmont Investment Advisors first reported a position in ACRS in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 464 Aclaris Therapeutics shares in Q3 2018, an estimated $9K.
  • Piedmont Investment Advisors first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Aclaris Therapeutics position peaked at $9K in Q2 2018.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.